Genitourinary cancer｜司会・講師のご紹介

Genitourinary cancer｜Discussion

解説【LBA1】A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

北村 寛　Kitamura Hiroshi
（富山大学 学術研究部医学系 腎泌尿器科学）

解説【LBA66】UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA-617 and Docetaxel (D) versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

北村 寛　Kitamura Hiroshi
（富山大学 学術研究部医学系 腎泌尿器科学）

解説【LBA73】Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Study

竹村 弘司　Takemura Kohji
（虎の門病院 臨床腫瘍科）

解説【LBA75】Prospective randomised phase-II trial of Ipilimumab/Nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

北村 寛　Kitamura Hiroshi
（富山大学 学術研究部医学系 腎泌尿器科学）

解説【LBA5】A randomized phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)

竹村 弘司　Takemura Kohji
（虎の門病院 臨床腫瘍科）

解説【LBA84】TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): interim analysis of SunRISe-4 (SR-4)

竹村 弘司　Takemura Kohji
（虎の門病院 臨床腫瘍科）